Roche Holding AG
SIX:ROG

Watchlist Manager
Roche Holding AG Logo
Roche Holding AG
SIX:ROG
Watchlist
Price: 329.6 CHF 1.38% Market Closed
Market Cap: 266.7B CHF

Net Margin
Roche Holding AG

15.3%
Current
18%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
15.3%
=
Net Income
9.4B
/
Revenue
61.6B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
CH
Roche Holding AG
SIX:ROG
262.5B CHF
15%
US
Eli Lilly and Co
NYSE:LLY
1T USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
499.6B USD
27%
UK
AstraZeneca PLC
LSE:AZN
212B GBP
16%
CH
Novartis AG
SIX:NOVN
211.3B CHF
26%
US
Merck & Co Inc
NYSE:MRK
265.6B USD
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK
33%
IE
Endo International PLC
LSE:0Y5F
212.8B USD
-126%
US
Pfizer Inc
NYSE:PFE
142.7B USD
16%
FR
Sanofi SA
PAR:SAN
99.3B EUR
21%
No Stocks Found

Roche Holding AG
Glance View

Roche Holding AG, a titan in the world of healthcare, operates from its headquarters in Basel, Switzerland. Established in 1896, Roche has grown into one of the world's leading pharmaceutical and diagnostics companies, driven by a steadfast commitment to advancing medicine and improving lives. Its unique business model is built on two primary pillars: Pharmaceuticals and Diagnostics. The pharmaceutical division focuses on discovering and developing medicines for cancer, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. A significant portion of its revenue is generated from innovative oncology drugs, which positions Roche as a global leader in cancer treatment. The company's investment in research and development is notably high, emphasizing its dedication to scientific discovery. On the diagnostics front, Roche continually advances its technologies to enhance disease detection and monitoring. This division creates and sells a wide array of diagnostic products and services, ranging from clinical chemistry and immunoassays to molecular biology and tissue diagnostics. By serving hospitals, research labs, and healthcare professionals, Roche Diagnostics aims to make a crucial impact on patient care and health system efficiency. This dual focus on pharmaceuticals and diagnostics allows Roche to capitalize on synergies between drug development and patient diagnostics, often integrating their advancements to provide more tailored and efficient healthcare solutions. The company's financial strength and strategic innovation are underpinned by its ability to adapt to changing market dynamics, ensuring its place as a stalwart in the global healthcare industry.

ROG Intrinsic Value
448.18 CHF
Undervaluation 26%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
15.3%
=
Net Income
9.4B
/
Revenue
61.6B
What is the Net Margin of Roche Holding AG?

Based on Roche Holding AG's most recent financial statements, the company has Net Margin of 15.3%.

Back to Top